Unity Biotechnology Inc

Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

24-week UBX1325 Phase 1 data presented at Angiogenesis, Exudation, and Degeneration 2022 Conference

UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023

UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement licensing its α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization.

UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects some investor sentiment shift to begin at this point for this "underfollowed" stock.

Why Did Mizuho Upgrade This Biotech Stock Focused On Age-Related Eye Diseases?

UBX1325 Phase 2 study in DME currently enrolling, with additional Phase 2 study in AMD planned for 1H22

UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates

Patients with diabetic macular edema in higher dose cohorts showed a mean BCVA gain of approximately 10 ETDRS letters sustained through 24 weeks after a single intravitreal injection

UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from October 19, 2021, through November 2, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted two new employees stock-based awards covering an aggregate of 190,000 shares of UNITY common stock, including options to purchase an aggregate of 160,000 shares of UNITY common stock and one grant consisting of 30,000 restricted stock units which will vest on the one-year anniversary of the vesting commencement date. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

UNITY Biotechnology Reports Granting of New Employment Inducement Awards

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial.  The data show strong and sustained responses following a single injection of UBX1325.

Unity Biotechnology Stock Falls After Updated Data From Wet AMD Candidate

16 th Annual Citi BioPharma Conference on September 8-10, 2021

UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C. Wainwright Ophthalmology Virtual Conference.

UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD)

UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates

SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, Inc. ("UNITY", NASDAQ:UBX), has reported encouraging data from a Phase I clinical study of UBX1325, an investigational Bcl-xL inhibiting compound, in patients with certain advanced vascular eye diseases, and has already dosed the first patient in the subsequent Phase IIa clinical study.

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases.

A Look At Unity's UBX1325 Phase 1 Results

UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325

UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease

Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ:UBX).

Takeaways On Unity Biotech's Clinical Data From A Bull Analyst

-  UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity

UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates

UBX1325's selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held May 1-7, 2021. In addition, Przemyslaw (Mike) Sapieha, Ph.D., chief scientific advisor for UNITY, will participate in a special interest panel on diabetic retinopathy.

UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2020.

UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following upcoming March virtual investor conferences:

UNITY Biotechnology to Participate in Upcoming March Investor Conferences

Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its licensee,...

Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

Aurinia Pharmaceuticals

Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs

Unity Biotech, Aurinia Among Pharma Companies With R&D Flops in 2020

Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY's Board

UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O'Neill, M.B., to the Board of Directors

Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on August 17 due to it failing to meet its primary endpoint in Unity's ongoing Phase 2 for that indication.

News for Unity Biotechnology Inc Stock (UBX)